Page Menu

Primary Appointments

  • Victor Ambros

    Victor Ambros, PhD

    We study gene regulatory mechanisms controlling the timing of animal development, using the C. elegans model system. Developmental timing regulators in C. elegans include microRNAs that control the stage-specific expression of key transcription factors. We aim to understand the molecular mechanisms of post-transcriptional gene regulation by microRNAs, and how microRNAs function in regulatory networks affecting development and disease.

  • Raffi Aroian

    Raffi Aroian, PhD

    The Aroian Group researches infectious diseases and parasites. Our mission is to discover new cures and new basic information that leads to cures for major diseases that afflict humankind, namely intestinal roundworms and bacterial pathogens.

  • Michael Brehm

    Michael Brehm, PhD

    Our laboratory studies the biological mechanisms that control human immune responses to infectious agents and transplanted non-self tissues. To investigate these mechanisms we are using humanized mouse models that contain functional human immune systems. The humanized mice are generated using immnodeficient mice, which are engrafted with either human hematopoietic stem cells or with mature human immune cells. These humanized mouse models allow the direct study of human immunity that is not possible with patients.

  • Craig Ceol

    Craig Ceol, PhD

    Our laboratory is interested in the genetic and molecular mechanisms underlying tumor initiation and maintenance. We focus primarily on melanoma, using genetically-engineered zebrafish models and mammalian cultured cells to identify unique features of cancer cells that can potentially be used for diagnostic, prognostic or therapeutic benefit.

  • Silvia Corvera

    Silvia Corvera, MD

    Our laboratory is interested in understanding the basic physiopathology of type 2 diabetes, specifically the role of adipose tissue physiology in diabetes pathogenesis.

  • Michael Czech

    Michael Czech, PhD

    Our laboratory group is dedicated to the discovery of molecular mechanisms whereby insulin signaling regulates energy homeostasis. This quest includes RNAi screens, digital imaging and TIRF microscopy, phenotyping mice with gene knockouts and analysis of human adipose tissues. We hope to translate our findings to the prevention and treatment of type 2 diabetes.

  • Roger Davis

    Roger Davis, PhD

    The cJun NH2-terminal kinase (JNK) signal transduction pathway is implicated in several stress-related disease processes including cancer, diabetes, inflammation, and stroke. Our hope is that drugs targeting the JNK pathway may be useful for the treatment of these diseases. The goal of this laboratory is to understand the molecular processes that are engaged by JNK in both health and disease.

  • Stephen Doxsey

    Stephen Doxsey, PhD

    Our laboratory investigates the mechanisms of centrosome function, spindle organization, cell cycle progression/checkpoints, cell separation during cytokinesis and asymmetries generated during mitosis. We are interested in the relationship of these processes to cancer, stem cell self-renewal, cancer stem cells and human aging.

  • Kevin Fogarty

    Kevin Fogarty, MS

    Research in this lab is concerned with the both the development and the application of light microscopy and imaging in cell biology and biophysics. Some driving problems include imaging the molecular components driving endocytosis and exocytosis/secretion in various cell types, and the imaging of intracellular calcium signaling in excitable cells such as smooth muscle cells, chromaffin cells, and neurons.

  • Manuel Garber

    Manuel Garber, PhD

    Manuel Garber, PhD, associate professor of molecular medicine and bioinformatics and integrative biology, and director of the Bioinformatics Core. Dr. Garber’s methods have been critical to the discovery and characterization of a novel set of large intergenic non-coding RNAs (lincRNAs) and to our understanding of the immune transcriptional response to pathogens. In September 2012, Dr. Garber moved to the University of Massachusetts Medical School to establish his laboratory and direct the Bioinformatics core.

  • Paul Greer

    Paul Greer, PhD

    We are broadly interested in the fundamental questions of how animals sense and interpret chemical signals to generate appropriate organismal responses and how these processes are disrupted in human neurological disorders. To address these questions we are exploring novel mechanisms by which the olfactory system senses behaviorally relevant external stimuli and characterizing the function of microglia in detecting internal chemical cues.

  • Dale Greiner

    Dale Greiner, PhD

    Our lab studies human immune responses, both how to turn them off for the treatment of type 1 diabetes and autoimmunity and conversely, to use the same pathways to turn the immune response on for the treatment of cancer. We utilize our unique animal models of human immune responses for investigating these approaches to down regulate as well as activate the human immune system.

  • David Guertin

    David Guertin, PhD

    We study the molecular basis of growth and how defects in growth regulatory pathways contribute to cancer, metabolic disorders, and aging. In particular we are trying to understand how cells simultaneously sense nutrient availability, energy levels, and growth factors and use this information to control cell metabolism, cell growth, and cell proliferation. Our approach is multidisciplinary and employs genetic, cell biological, and biochemical strategies using mice, stem cells, and established mammalian cell lines.

  • Tony Ip

    Tony Ip, PhD

    We use Drosophila melanogaster, the common fruit fly, as a model to study innate immune response and stem cell regulation in the adult intestinal tract. The intestinal tract of the adult fly is a relatively simple organ formed by a layer of epithelial cells interspersed with stem cells. The intestinal tract frequently faces environmental challenges such as pathogenic chemicals and microbes. We are studying how these pathogens stimulate innate immune response and stem cell division, both of which are essential for the survival of the animal.

  • Elinor Karlsson

    Elinor Karlsson, PhD

    My research uses evolution as a tool for understanding how the human genome works. By combining signals of natural selection with genome-wide association studies, I aim to identify genes, pathways, and the functional variants underlying polygenic diseases, and translate these discoveries into advances in human health care. I am currently applying these methods to understand infectious disease resistance in humans, such as cholera resistance in Bangladesh, as well as behavioral genetics in dogs.

  • Jason Kim

    Jason Kim, PhD

    Our research investigates obesity, diabetes and its complications using elegant metabolic procedures and transgenic mouse models of altered metabolism. Our NIH-funded projects examine the role of inflammation in insulin resistance and cardiovascular diseases. The goal of our research is to understand how obesity causes diabetes and to find its cure.

  • David Lambright

    David Lambright, PhD

    Crystallographic, biophysical, biochemical, and cell biological approaches are used to investigate mechanisms of membrane trafficking and cell signaling. Defects in these fundamental regulatory mechanisms play critical roles in genetically linked disorders and complex disease states including cancer and diabetes.

  • Michael Lee

    Michael Lee, PhD

    Treatment of many human diseases, including cancer, typically involves modulation of signal transduction pathways. These pathways are functionally integrated, very plastic, and incredibly sensitive to environmental context. Our group uses a combination of experimental and computational approaches to study the organization and function of signaling networks controlling the growth, survival, and death of cancer cells. We are particularly interested in understanding the adaptive properties that cells engage when faced with anti-cancer drugs, as well as identifying genetic, non-genetic, and contextual factors that contribute to the therapeutic variability seen in cancer patients.

  • Jeremy Luban

    Jeremy Luban, MD

    Distinguished physician–scientist Jeremy Luban, MD has been appointed professor of molecular medicine at UMass Medical School and the David L. Freelander Memorial Professor in HIV/AIDS Research. Dr. Luban’s research focuses on understanding host cell factors that contribute to HIV viral replication. He has identified Cyclophilin A and Trim 5 among more than thirty HIV-1 regulatory host factors. His work will contribute to the development of drugs and vaccines targeting HIV virus infections and other disease states. NIH/NIDA named him a 2012 Avant-Garde Awardee for HIV/AIDS research.

  • Katherine Luzuriaga

    Katherine Luzuriaga, MD

    Research in the laboratory is focused on understanding viral and host factors that contribute to the establishment of persistent viral infections in humans, including human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV).

  • Rene Maehr

    Rene Maehr, PhD

    Type 1 Diabetes (T1D) is the result of an autoimmune destruction of insulin producing, pancreatic beta cells. The events leading to the disease have usually occurred long before diagnosis and are based on complex interactions between genes and the environment. The currently available rodent models for T1D can only represent a limited number of patients leaving open the question how many different types of T1D exist. To overcome these difficulties and expand our understanding of T1D and other diseases targeting the immune system we are building in vitro models using human pluripotent stem cells. In those stem cell-based model systems genetic and developmental aspects of the disease can be elucidated. The long-term goal is to recapitulate the disease in a patient-specific manner and to identify novel treatment strategies.

  • Amir Mitchell

    Amir Mitchell, PhD

    Our lab studies the response of cellular networks to changing environments in health and disease. While the structure of regulatory pathways is studied extensively, far less is known about network re-organization under time-varying stimuli. Yet this under-explored dimension has broad implications – time-variant stimuli can culminate in extreme outcomes, from detrimental signaling catastrophes to anticipatory stress responses. We combine experimental and theoretical approaches to dissect network functionality and uncover its unique points of failure. We aim to exploit the network structure to therapeutically target subpopulations of diseased cells within a healthy host.

  • Gary Ostroff

    Gary Ostroff, PhD

    Our laboratory works at the interface of nanomaterial science and biology to develop oral DNA, siRNA, protein and small molecule delivery technologies based on beta-glucan particles processed into porous hollow microspheres loaded with multi-layered nanostructured payload complexes. We collaborate with many investigators to develop research and translational applications for this delivery technology targeting chronic diseases using gene therapy, RNAi, vaccine and small molecule inhibitor approaches.

  • Gregory Pazour

    Gregory Pazour, PhD

    We are interested in the function of the mammalian primary cilium. These organelles play vital roles in the development of mammals and in the etiology of diseases such as polycystic kidney disease and blindness. Our work combines in vitro cell culture studies with mutant mouse models to understand the role of cilia in controlling kidney architecture and formation of the photoreceptor outer segment.

  • Craig Peterson

    Craig Peterson, PhD

    Work in the lab is focused on understanding how chromosome structure influences gene transcription, DNA replication and repair, with special emphasis on identifying and characterizing the cellular machines that control chromosome dynamics. We use a combination of chromatin biochemistry, analytical ultracentrifugation, and yeast molecular genetics.

  • Joel Richter

    Joel Richter, PhD

    Our lab studies the biochemistry of post-transcriptional gene expression, particularly cytoplasmic polyadenylation and translational control. We also examine how these processes influence early animal development, cell division and cellular senescence, and neuronal synaptic plasticity and memory consolidation.

  • Caterina Strambio

    Caterina Strambio, PhD

    Caterina Strambio De Castillia grew up in Italy and received her Laurea in Biologia (equivalent to B.S./M.S.) from the University of Pavia in 1988. She obtained her Ph.D. (1992-1998) working with Gunter Blobel at The Rockefeller Universitycore. Her work has been supported by the American Cancer Society, the European Union and the Swiss National Science Foundation. In 2012, Dr. Strambio De Castillia joined the Program in Molecular Medicine at the University of Massachusetts Medical School.

  • John Sullivan

    John Sullivan, MD

    Dr. Sullivan, a founding faculty member of the Program in Molecular Medicine, was appointed Emeritus Professor of Molecular Medicine in 2019. Dr. Sullivan has an established record as a physician scientist in the fields of immunology and virology. He currently serves as the Chief Scientific Advisor for the Program in Molecular Medicine and Associate Director of Mentoring for the Medical Scientist Training Program.

  • William Theurkauf

    William Theurkauf, PhD

    Work in the lab addresses RNA localization and embryonic patterning, the response of mitotic cells to DNA damage, and small RNA function in germline development. Studies combine high resolution imaging, genetic, and molecular approaches in Drosophila and mammalian cultured cell systems.

  • Marian Walhout

    Marian Walhout, PhD

    We aim to understand how regulatory networks control animal development, function, and homeostasis; and how dysfunctional networks affect or cause diseases like diabetes, obesity and cancer. We use a combination of experimental and computational systems biology methods to map, characterize and manipulate regulatory networks, most notably in the nematode C. elegans.

  • Amy Walker

    Amy Walker, PhD

    Using C. elegans and mammalian models, we study how lipid homeostasis is affected by genetics or diet and how transcriptional control of methyl donor supply may affect cellular processes such as epigenetics. We also examine links between metabolism and cellular function potentially contributing to human metabolic disorders.

  • Ruijia Wang

    Ruijia Wang, PhD

    Our bioinformatics core develops and applies algorithms and toolkits to analyze and integrate large-scale next-gene sequencing (NGS) datasets, including those generated from high-throughput experiments such as ChIP-seq, RNA-seq, NET-seq, chRNA-seq, iCLIP, single-cell RNA-seq and 3’end Sequencing. We provide bioinformatics solutions to not only construct the expression, splicing, polyadenylation, RBP binding, and histone modification profiles, but also to capture genomic and transcriptomic features such as sequence motifs, mutations, splicing score, intron size, target and binding sites involved in the regulatory mechanism for transcriptional, medical and clinical research. 

  • Maria Zapp

    Maria Zapp, PhD

    An essential and characteristic step in human immunodeficiency virus type-1 (HIV-1) replication is the export of the intron-containing gag-pol and env mRNAs from the nucleus to the cytoplasm. The viral regulatory protein Rev mediates this event, in conjunction with the cellular nuclear export machinery and several protein cofactors. Our long-term objective is to gain a detailed understanding of the cellular factors and molecular mechanisms involved in Rev-directed nuclear export, cytoplasmic localization, and function of HIV-1 RNAs.

Additional Resources
click to open search panel